Life Science News

Bausch Health, Canada part of Bausch Health Companies Inc. (NYSE: BHC) (TSX: BHC), ("Bausch Health" or the "Company") today announced the availability through pharmacies across Canada of its new prescription treatment TRULANCE® (plecanatide).

TRULANCE(R) product package (CNW Group/Bausch Health)

TRULANCE is approved by Health Canada for the treatment of irritable bowel syndrome with constipation (IBS-C) in adults, 2 and is the first treatment brought to market in Canada by the gastrointestinal division of the Company. Canadian treatment guidelines for IBS-C recommend a variety of non-pharmaceutical and pharmaceutical approaches to treatment, 3 but 70 per cent of surveyed IBS-C patients report no treatment had thus far completely relieved their symptoms. 4

"Bausch Health, Canada is proud to launch TRULANCE as the first therapy brought to the Canadian market in an area where there is a great unmet need for Canadian patients and for a condition for which the prevalence in Canada is one of the highest in the world," said Ginette Gagné, interim president and general manager and vice president, Finance, Bausch Health , Canada . "We know doctors are seeking alternatives to improve care for those Canadians with the often-debilitating symptoms of IBS-C."

TRULANCE provides a solution to the treatment gap currently experienced by patients suffering from IBS-C.

In a recent survey of IBS-C patients across Canada , almost three out of four (72 per cent) said not all their symptoms are under control. Almost six out of 10 (57 per cent) said their symptoms prevent them from enjoying their daily activities and roughly the same number (56 per cent) feel their symptoms prevent them from reaching their full potential in life. 5 The seriousness and impact of IBS symptoms is reflected in a 2018 survey in which Canadians with IBS reported they would give up 25 per cent of their remaining life (15 years) to live a symptom-free life. 6

"Many people with IBS-C suffer in silence or with unsatisfactory treatments, because it is not a life-threatening acute disease, but it does have a big impact on their lives," said Dr. Louis Liu , chief, Division of Gastroenterology and Hepatology, University Health Network, Toronto . "It often affects people in early-to-middle age during the very busy and productive part of their lives, so it is important that it gets treated to the best extent possible, which is why having a new treatment option is very useful."

"We welcome a new treatment for IBS-C for Canadians, because we know current treatment options are not meeting the needs of every person with this condition," said Gail Attara , chief executive officer of the Gastrointestinal Society. "Our own large survey of persons living with IBS showed that only one in five felt confident their symptoms were under control. 7 This clearly demonstrates a dire need for new treatment options for those who are living with this invisible condition."

"With the prevalence of IBS being so high in Canada , we are thrilled to hear there is a new treatment option available to help Canadians manage the symptoms and severity of IBS-C," said Kelsey Cheyne , executive director of the Canadian Digestive Health Foundation. "This works towards our vision to help empower all Canadians to manage their digestive health with confidence and optimism."

About irritable bowel syndrome with constipation (IBS-C)
Irritable bowel syndrome (IBS) involves frequent and intense symptoms of abdominal cramping, bloating, constipation or diarrhea to the extent that they interfere with day-to-day living. 8 IBS-C is one of four subtypes of IBS, which occurs when the digestive system contracts slowly, delaying transit time for products of digestion, resulting in hard, difficult to pass, infrequent stools (constipation). The other forms are IBS-D (diarrhea) and IBS-M (mixed, both constipation and diarrhea symptoms) and IBS-U (unclassified). Constipation-predominant IBS represents about 30% of IBS cases. 9

IBS affects up to one in five Canadians at any given time 10 and Canada has one of the highest prevalences of the condition in the world. 11 The lifetime risk for a Canadian to develop IBS is 30%, with it affecting 20% of the population at any given time, and in Canada and most Western nations, IBS arises significantly more frequently in women than in men. 12 Two-thirds (67%) of Canadians with IBS-C say their symptoms make them feel self-conscious, and 60% say it is difficult for them to plan things, because they never know when their symptoms will act up; half (51%) say their symptoms cause them to stay home often. 13

About TRULANCE ® (plecanatide tablets) in Canada
TRULANCE is a guanylate cyclase-C agonist, which mimics the effect of natural hormones in the body, giving it a unique method of action which allows it to act in the small intestine in a pH-sensitive manner to facilitate fluid secretion, increase intestinal transit, and decrease the activity of pain-sensitive nerves in the intestines. 14 In clinical studies, TRULANCE provided a statistically significant patient self-evaluated reduction in IBS disease severity and a statistically significant reduction in IBS symptoms versus placebo. 15 In the two clinical trials on which the approval of TRULANCE was based, 30.2 per cent and 21.5 per cent respectively of TRULANCE patients were considered overall responders, meaning they experienced both a significant decrease in abdominal pain and a significant increase in complete spontaneous bowel movements compared to those on placebo. 16 In clinical trials, the incidence of serious adverse events in patients using TRULANCE was low (0.8 per cent) and similar to that recorded in the placebo arm of the studies. 17 TRULANCE has not been studied in or approved for patients under the age of 18. 18

About the IBS-C patient survey 19
Statistics about the current attitudes and experiences of Canadians with IBS-C come from a comprehensive survey commissioned by Bausch Health, Canada in September and October 2021 and conducted by the research firm Callosum. The survey received data from 784 Canadians aged 18 and older who have been diagnosed with IBS-C specifically or have diagnosed with IBS generally but have symptoms of constipation. The average age of respondents was 47 years; 72% were females and 28% were males, reflecting the greater incidence of IBS-C among females. Respondents came from all regions of Canada in very close proportion to each region's respective share of the Canadian population.

About Bausch Health Companies Inc.
Bausch Health Companies Inc. (NYSE/TSX: BHC ) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. In Canada, the Company's prescription product portfolio is focused on eye health, dermatology, and cardio-metabolic conditions. More information can be found on the Company's website at bauschhealth.ca .


_____________________
REFERENCES


1.

Bausch Health, Canada, Understanding Patients' Perceptions and Treatment Habits of IBS-C , research report by
Callosum, October 2021, p. 15.


2.

Bausch Health, Canada, TRULANCE Product Monograph dated March 17, 2021, Indications, p. 4.


3.

Moayyedi P et al, Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of
Irritable Bowel Syndrome (IBS), Journal of the Canadian Association of Gastroenterology , 2019, 2(1), 6–29.


4.

Bausch Health, Canada, Understanding Patients' Perceptions and Treatment Habits of IBS-C , research report by
Callosum, October 2021, p. 15.


5.

Bausch Health, Canada, Understanding Patients' Perceptions and Treatment Habits of IBS-C , research report by
Callosum, October 2021, p. 14.


6.

Canadian Digestive Health Foundation, Irritable Bowel Syndrome Statistics, https://cdhf.ca/digestive-
disorders/irritable-bowel-syndrome-ibs/statistics/
.


7.

Gastrointestinal Society. 2016 Survey Results Irritable Bowel Syndrome (IBS). https://badgut.org/ibs-survey-
results/
.


8.

Gastrointestinal Society, Irritable Bowel Syndrome (IBS), https://badgut.org/information-centre/a-z-digestive-
topics/ibs/
.


9.

Ibid.


10.

Ibid.


11.

Canadian Digestive Health Foundation, Irritable Bowel Syndrome Statistics, https://cdhf.ca/digestive-
disorders/irritable-bowel-syndrome-ibs/statistics/
.


12.

Gastrointestinal Society, Irritable Bowel Syndrome (IBS), https://badgut.org/information-centre/a-z-digestive-
topics/ibs/
.


13.

Bausch Health, Canada, Understanding Patients' Perceptions and Treatment Habits of IBS-C , research report by
Callosum, October 2021, p. 14.


14.

Bausch Health, Canada, TRULANCE Product Monograph dated March 17, 2021, Mechanism of Action, p. 11-12.


15.

Bausch Health, Canada, TRULANCE Product Monograph dated March 17, 2021, Clinical Trials, Patient Global
Rating (PGR) Assessments, p. 19


16.

Bausch Health, Canada, TRULANCE Product Monograph dated March 17, 2021, Study Results, p. 16.


17.

Bausch Health, Canada, TRULANCE Product Monograph dated March 17, 2021, Adverse Reactions Overview, p.
9


18.

Bausch Health, Canada, TRULANCE Product Monograph dated March 17, 2021, Pediatrics, p. 4.


19.

Bausch Health, Canada, Understanding Patients' Perceptions and Treatment Habits of IBS-C , research report by
Callosum, October 2021.


________________________

THE BURDEN FOR CANADIANS OF IRRITABLE BOWEL SYNDROME WITH CONSTIPATION (IBS-C) (CNW Group/Bausch Health)

SOURCE Bausch Health

Cision View original content to download multimedia: http://www.newswire.ca/en/releases/archive/February2022/08/c9054.html

News Provided by Canada Newswire via QuoteMedia

BHC:CA,BHC

Medtronic to announce financial results for its fourth quarter and full fiscal year 2022

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced that it will report financial results for its fourth quarter and full fiscal year 2022 on Thursday, May 26, 2022 . A news release will be issued at approximately 5:45 a.m. Central Daylight Time (CDT) and will be available at https:news.medtronic.com . The news release will include summary financial information for the company's fourth quarter and full fiscal year 2022, which ended on Friday, April 29, 2022 .

Medtronic will host a video webcast at 7:00 a.m. CDT on Thursday , May 26, 2022, to discuss financial results for its fourth quarter and full fiscal year 2022. The webcast can be accessed at https://investorrelations.medtronic.com .

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

New Late-Breaking Data Highlight Abbott Structural Heart Transcatheter Valve Therapies

  • Data presented at EuroPCR 2022 reinforce the impact of Abbott's minimally invasive heart devices on patient outcomes and quality of life
  • Findings demonstrate TriClip™ transcatheter edge-to-edge (TEER) repair is effective at reducing tricuspid regurgitation across a broad range of anatomies
  • One-year outcomes for Navitor™ transcatheter aortic valve implantation (TAVI) system show the safety and effectiveness of this therapy and durable performance of the sealing cuff in minimizing paravalvular leak for patients with severe aortic stenosis

Abbott (NYSE: ABT) today announced two late-breaking data presentations highlighting both TriClip™, a first-of-its kind minimally invasive tricuspid heart valve repair device, and Navitor™, the company's latest-generation transcatheter aortic valve implantation (TAVI) system. The company also showcased new data for MitraClip™ and Amplatzer™ Amulet™, two key components of the company's industry-leading structural heart portfolio.

All data were presented at EuroPCR, the annual meeting of the European Association of Percutaneous Cardiovascular Interventions, held in Paris from May 17-20, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

Thermo Fisher Scientific Declares Quarterly Dividend

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that on May 18, 2022, its Board of Directors authorized a quarterly cash dividend of $0.30 per common share, payable on July 15, 2022, to shareholders of record as of June 15, 2022.

About Thermo Fisher Scientific

News Provided by Business Wire via QuoteMedia

Keep reading...Show less
Premier Health Reports FY2022 Second Quarter Results

Premier Health Reports FY2022 Second Quarter Results

Premier Health of America Inc. (TSXV: PHA ) (the " Corporation "), a leading Canadian Healthtech company, announces it has filed its Condensed Interim Consolidated Financial Statements and Management Discussion and Analysis for its second quarter ended March 31, 2022.

Summary

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Salix Pharmaceuticals To Share New Data At Digestive Disease Week® 2022

XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU ® Research Posters Will Be Presented

Bausch Health Companies Inc. (NYSETSX: BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals, ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and disorders, today announced seven posters on behalf of XIFAXAN® (rifaximin), TRULANCE® (plecanatide) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution), will be shared at Digestive Disease Week® (DDW) 2022 which is being held virtually and in-person in San Diego, Calif. from May 21-24, 2022 . The posters will be accessible on DDW's ePoster's website beginning Saturday, May 21, 2022 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less

EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News

×